A phase 1, open-label single site study of comparison between pharmacokinetics of a dry-powder inhaler (DPI) CBD formulation and oral CBD solution in healthy participants
Latest Information Update: 24 Aug 2021
At a glance
- Drugs Cannabidiol (Primary) ; Cannabidiol (Primary)
- Indications Cerebral ischaemia; Dravet syndrome; Epilepsy; Heroin-related disorders; Infantile spasms; Lennox-Gastaut syndrome; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Rett syndrome; Schizophrenia; Tuberous sclerosis
- Focus Pharmacokinetics
- 24 Aug 2021 Results published in the Journal of Pharmaceutical Sciences
- 24 Aug 2021 New trial record